Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aphios, a biotechnology company, has secured an exclusive license from Louisiana State University Health Sciences Center at Shreveport, Louisiana for intellectual property and know-how for treating chronic inflammatory diseases and organ rejection caused by transplantation mediated organ stress.
Subscribe to our email newsletter
Scientists at Louisiana State University have discovered that bryostatin-1, a potent PKC modulator at nanomolar concentrations, activates protein kinase C-delta (PKC-delta) causing a near complete blockade of leukocyte (white blood cell) infiltration.
This activation and therapeutic response can be achieved by injecting bryostatin-1 directly into chronically inflamed tissues, treating the skin with bryostatin-1, or perfusing organs with bryostatin-1 prior to transplantation and cold storage, said Aphios.
According to the company, this invention relates to pharmaceutical compositions, particularly pharmaceutical compositions comprising bryostatin-1, other bryostatins and substituted derivatives of bryostatins for use in treating inflammation, and for use in combating arteriosclerosis, diseases of the cardiovascular system and the central nervous system, prior to and following organ transplantation, and ischemia (US patent pending).